Actualités

Merck stock snapshot after recent performance Merck (MRK) has drawn investor attention after a period of steady share price movement, with the stock closing at US$120.79 and recording positive returns over the past week, month and past 3 months. At the same time, Merck reports annual revenue of US$65.8b and net income of US$8.9b, with both metrics showing annual growth. These figures help frame how recent price action lines up with the company’s current scale and profitability. See our latest...

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.

Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc. (NYSE:MRK) announced on June 1 detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene in combination with KEYTRUDA® in patients with high-risk melanoma following […]

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.

Erasca Inc. (NASDAQ:ERAS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Erasca Inc. (NASDAQ:ERAS) announced a supply agreement and a clinical trial partnership with Merck. The collaboration is aimed at facilitating the AURORAS-1 clinical proof-of-concept research. This research thoroughly assesses the exclusive pan-RAS molecular glue ERAS-0015 […]

The seasonal strength lines up with major medical and scientific conferences that cluster during this period.

Merck (NYSE:MRK) has agreed to a settlement worth more than $50m to resolve over 200 lawsuits related to its Gardasil HPV vaccine. The settlement concludes a significant block of litigation while Merck continues to state that Gardasil is safe and effective. This development comes as Merck's share price stands at $120.26 and the stock has returned 60.6% over the past year. For investors watching Merck, the Gardasil settlement is a material legal event that helps clear a long running source...

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's positive momentum was extended as the company, along with partner Merck, presented positive long-term data for its personalized mRNA-based cancer vaccine.

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.

Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2%

In the last week, the United States market has stayed flat, yet it is up 26% over the past year with earnings forecast to grow by 17% annually. In such a robust market environment, identifying stocks trading below their intrinsic value can present unique opportunities for investors seeking potential growth.

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.

US stocks were expected to head in different directions on Thursday morning, as oil prices retreat but tech earnings overnight disappointed investors. Dow Jones futures were called 0.8% higher, but the S&P 500 was off 0.4% and Nasdaq futures were down 1.3%. The latter pair were...

The United States market remained flat over the last week but has seen a 26% increase over the past year, with earnings forecast to grow by 17% annually. In such a market environment, identifying stocks that are trading below their fair value can offer potential opportunities for investors seeking to capitalize on future growth prospects.

Major stock indexes finished mostly higher Thursday, even though Broadcom and other AI chipmaker stocks sank.

FTSE 100 up 8 points to 10,341 Oil prices soften on Israel-Lebanon ceasefire CMC Markets nears five-year high on results 2.56pm: Toddlers' picnic on Wall Street As expected, Wall Street has opened like a toddlers' picnic, with everyone heading off in different...

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks With Remarkable Resilience. Moderna snapped a four-day losing streak on Wednesday, jumping 7.49 percent to finish at $49.06 apiece, as investors positioned portfolios ahead of its participation in a conference next week. In a notice to investors, Moderna Inc. (NASDAQ:MRNA) said that it is set to […]

Erasca Inc. (NASDAQ:ERAS) is one of the best growth stocks under $20 to buy. On May 11, Erasca reported positive progress for its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for its lead candidate, ERAS-0015, in KRAS G12X lung and pancreatic cancers. The company is accelerating development, having already initiated monotherapy […]

Over the last 7 days, the United States market has risen by 1.2%, contributing to a significant 27% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, identifying stocks that are potentially trading below their estimated value can offer investors opportunities for growth and diversification.

Analysts have been nudging Merck price targets higher, with some moves running from US$135 to US$150, while the core fair value model remains anchored at US$129.74 per share. These target changes are closely tied to how researchers view the potential of pipeline assets like Sac TMT and TERN-701, alongside the risks around trial outcomes and deal terms. As you read on, you will see how to track these shifting views and what they might mean for your own Merck thesis over time. Stay updated as...

GSK's Specialty Medicines business is the company's primary growth driver, supported by HIV leadership, new drug launches and a deep late-stage pipeline.

AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.